Cabinet de groupe
Saint-Maur-des-Fossés, Saint Maur, 94100, France
Location status: Recruiting
NCT Number: NCT05847036
Urinary tract infections (UTIs) are one of the most common bacterial infections managed in general practice: they are the 2nd site of community-acquired bacterial infection after respiratory infections (4-6 million consultations per year in France).
UTIs represent 15% of total antibiotic prescriptions in France. Antibiotics recommended for UTIs, except for cystitis, are considered as "critical" (highly generating bacterial resistances). UTIs are a potential source of antibiotic resistance: often inappropriate antibiotic prescriptions, evolution of the resistance profiles of the bacteria involved, emergence of multi-resistant strains.
The first hypothesis is that there are other profiles of clinical UTI situations in general practice than typical cystitis or pyelonephritis, including intermediate forms.
The second hypothesis is that these intermediate forms of UTI are subject to longer durations of antibiotherapy, and that probable explanatory factors need to be identified.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Saint-Maur-des-Fossés, Saint Maur, 94100, France
Location status: Recruiting
Urinary tract infections (UTIs) are one of the most common bacterial infections managed in general practice: they are the 2nd site of community-acquired bacterial infection after respiratory infections (4-6 million consultations per year in France).
UTIs represent 15% of total antibiotic prescriptions in France. Antibiotics recommended for UTIs, except for cystitis, are considered as "critical" (highly generating bacterial resistances). UTIs are a potential source of antibiotic resistance: often inappropriate antibiotic prescriptions, evolution of the resistance profiles of the bacteria involved, emergence of multi-resistant strains.
Current guidelines classify UTIs as "uncomplicated UTI" (cystitis and pyelonephritis) and "UTI at risk of complication" (cystitis, pyelonephritis and male UTI) [1-2]. However, in primary care, pathologies are diagnosed at an early stage: the clinical signs usually described by scientific societies are not always all found, and the descriptions are not always adapted to the realities encountered in general practice [3-6]. Some clinical situations do not fit into the systematic categories of the guidelines, with "intermediate" forms (such as pain in the lumbar fossae without fever "cysphritis" or other atypical presentations) [3]. The current literature in general practice highlights these issues: the need for prospective cohorts in real-life practice to identify these profiles and develop more appropriate guidelines [3-6]. Treatment for these intermediate forms is not obvious and is often empirical: potentially longer antibiotherapies, with possible worsening of antibiotic resistance [7].
The first hypothesis is that there are other profiles of clinical UTI situations in general practice than typical cystitis or pyelonephritis, including intermediate forms.
The second hypothesis is that these intermediate forms of UTI are subject to longer durations of antibiotherapy, and that probable explanatory factors need to be identified.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Non-inclusion Criteria:
Time frame: At Day 14 after the end of the Antiobiotic treatment
The primary outcome will be the rate and the clinical-bacteriological characteristics of the identified profiles of patients with UTI in general practice
Time frame: At Day 0, at Day 14 after the end of the treatment and between Day 0 and Day14 after the end of the treatment
Percentage of cytobacteriological examination of urine (CBEUs) prescribed
Time frame: At Day 0, at Day 14 after the end of the treatment and between Day 0 and Day 14 after the end of the treatment
Number of consultations (in general practice or other specialty) and reasons
Time frame: At Day 14 after the end of the treatment
Percentage of patients with worsening, stability or recovery of their symptoms as final condition (based on clinical assessment by GPs during a consultation at day 14)
Time frame: At Day 14 after the end of the treatment
Percentage of antibiotics prescribed, Choice of antibiotic class, whether 'delayed' or immediate, duration, posology
Contact information is provided by the study sponsor or research team.
Emilie FERRAT, Dr
CONTACT
Véronique ORCEL, Dr
CONTACT
CNGE Conseil
Other
Profiles of Urinary Tract Infections in General Practice : a Prospective Multicentre Cohort Study
Acronym: PODIUM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06976125
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Cleveland, Ohio, United States
View Trial DetailsNCT07559318
Antiobiotic Stewardship, Communicable Diseases
Melun, France
View Trial DetailsNCT05711446
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
New York, United States
View Trial DetailsNCT07435844
Calcinosis, Calcium Metabolism Disorders
Mariánské Lázně, Carlsbad Region, Czechia
View Trial Details